Cerebain Biotech (OTC: CBBT) is dedicated to pursuing the development and commercialization of novel treatment approaches in the fight against dementias, with a particular focus on Alzheimer’s Disease.
Our vision is to apply what we know about the effect of omentum stimulation on improved cognitive function to create a new and more effective treatment paradigm.
For the millions of people living with, or in fear of, an Alzheimer’s diagnosis, our success could mean hope for the future and a lifetime preserved.
Our goal is the development and commercialization of a medical device with the potential to arrest or significantly slow Alzheimer’s Disease progression.